Vivani Medical’s NPM-139: A Promising Semaglutide Implant with Strong Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Yi Chen reiterated a Buy rating for Vivani Medical's stock (VANI) due to the promising potential of their semaglutide implant, NPM-139, for chronic weight management. The company plans to start a Phase 1 clinical trial in early 2026. Preclinical studies show significant weight loss for over six months. Financial activities have strengthened the company's cash position. Maxim Group also maintained a Buy rating with a $4.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments